15%-20% of patients with chronic HCV infection will develop cirrhosis within 20 years after their encounter with the virus. 2 These patients have an increased risk of developing liver failure and hepatocellular carcinoma, associated with an increased mortality rate. 3 However, chronic HCV infection is a multifaceted disease, which is not restricted to the liver. Extrahepatic manifestations, including mixed cryoglobulinemic vasculitis and renal disease, may occur long before cirrhosis has been established. 4 Notably, the nonhepatic complications of HCV are clinically relevant, with a recent study documenting increased nonliver-related mortality among patients with HCV. 5 Until 2011, physicians depended on the administration of pegylated interferon alpha (PegIFN) and ribavirin (RBV) for the treatment of chronic HCV infection. These regimens were suboptimal in most patients and were associated with important safety issues. [6] [7] [8] The introduction of the first protease inhibitors, telaprevir (TVR) and boceprevir (BOC), for the treatment of HCV genotype 1 led to improved sustained virological response (SVR) rates. Although the registration trials reported a relatively benign renal safety profile, shortly after approval, data emerged on significant renal adverse events [9] [10] [11] [12] along with a more significant overall adverse event profile than that documented in the registration trials. [13] [14] [15] The approval of sofosbuvir (SOF), a very potent nucleotide analogue inhibitor of the HCV RNA-dependent RNA polymerase, has revolutionized the treatment of chronic HCV infection. SOF is active against all HCV genotypes and when combined with other direct-acting antivirals (DAAs) leads to very high rates of SVR in most patient populations. 16, 17 The main active metabolite of SOF, GS331007, is excreted by the kidneys, and higher drug and metabolite concentrations are found in those patients with an estimated glomerular filtration rate (eGFR)
<30 mL/min/1.73 m 2 or end-stage renal disease on hemodialysis. 18 Therefore, guidelines do not recommend the use of SOF in patients with an eGRF <30 mL/min or patients with end-stage renal disease, and recommend regular monitoring of renal function in patients receiving SOF. 19, 20 The major trials examining the safety and efficacy of SOF demonstrated an excellent renal safety profile, 16, 17, 21 however, whether this also applies in real-world clinical practice is currently unknown. Therefore, we aimed to examine the renal safety profile in patients treated with SOF-based therapies, and compared it to the profile of TVR/BOC-based antiviral therapy.
| PATIENTS AND METHODS

| Study population
This multicenter retrospective observational study included all consecutive patients who initiated treatment with a SOF-based or TVR/ BOC-based regimen prior to January 31, 2015. Patients were treated in the Toronto Centre for Liver Disease or the University of Arkansas for Medical Sciences. All included patients had available creatinine results before, during and after therapy and all creatinine levels were evaluated. Patients treated post-liver transplantation were excluded. All charts were reviewed by five investigators (RM, SA, JSK, SMH and KDR) to collect detailed data on baseline demographics, on-treatment laboratory results and clinical events and outcome of therapy.
| Definitions
On-treatment acute kidney injury (AKI) was defined as an increase of ≥0.3 mg/dL (≥26.5 lmol/L) or ≥50% in serum creatinine level when compared to baseline value. 22 Normalization of creatinine was considered whenever follow-up determinations were no more than 0.2 mg/dL (17.7 lmol/L) from baseline. 
| Outcomes
The primary outcome of this study was the occurrence of AKI during antiviral therapy with SOF-based and TVR/BOC-based regimens.
Secondary outcomes included factors associated with the occurrence of AKI, the influence of AKI on attaining SVR, and the on-treatment dynamics of creatinine among patients who experienced AKI. Creatinine levels returned to normal at end of follow-up in 52
| Statistical analyses
(86.6%) of the 59 patients who experienced AKI and had a creatinine level available at the end of follow-up. Among those patients without normalisation of creatinine, 3 (11.5%) were treated with a SOFbased regimen and 5 (15.2%) with a TVR/BOC-based regimen (see table 2 for patient characteristics). In patients who experienced AKI and had available creatinine level during follow-up, the mean difference in creatinine between baseline and follow-up was 0.06 mg/dL (5.3 lmol/L) (range: À0.30 to 0.90 mg/dL (À26.5 to 79.6 lmol/L)).
| Patients with pre-existing chronic kidney disease
There were 38 HCV patients with pre-existing chronic kidney disease treated with antivirals. Table S1 shows baseline characteristics of the 32 (7.5%) patients with a baseline eGFR between ≤60 and patients. There were four cases lost to follow-up. Six patients were treated with antivirals while on dialysis. Details regarding baseline characteristics and virological outcomes are shown in Table S2 . All patients continued on dialysis after completion of antiviral therapy.
| DISCUSSION
This multicenter study showed that AKI was observed in 11% of patients treated with a SOF-based regimen, which was lower than the 18% observed in patients treated with TVR/BOC-based regi- During the treatment period, no major adverse events were reported and 87% of the patients achieved SVR. 24 A report from the US included 17 patients with advanced renal disease who received fulldose SOF in addition to SMV. Fifteen of these patients were on dialysis and two were pre-dialysis. All patients achieved SVR, there were 26 Notably, the GS331007 metabolite did not accumulate beyond the first days of treatment and 53% was removed by dialysis. Although these three small studies did not report major safety issues, detailed information on creatinine levels during treatment was not discussed. Recently, data on the safety and efficacy of SOFbased regimens among 73 patients with an eGFR ≤45 mL/min/ 1.73 m 2 were reported from the HCV-TARGET registry. 27 Although they used only chart review rather than objective evidence of AKI, they found that the presence of impaired renal function (eGFR | 51 patients treated in clinical practice throughout the world. We identified an incidence of on-treatment AKI of 11%, which was associated with a trend toward a lower rate of SVR. It is likely that this finding can be explained by the fact that the patients who experienced AKI and did not attain SVR were patients with more advanced liver disease. Indeed, seven (87.5%) of the eight patients who did not attain SVR in this group had cirrhosis, of whom six had decompensated cirrhosis (data not shown). More importantly, three patients did not have reversible AKI after SOF-based therapy. However, when looking into more detail, creatinine levels did return to normal at SVR4, but subsequent elevations in creatinine were observed between SVR4 and SVR12.
It was not unexpected that the use of a TVR/BOC-based regimen was associated with a higher occurrence of AKI, as previous studies also showed that renal adverse events were not uncommon. 9, 10 Although they used another definition for acute kidney injury, Mauss et al. showed that up to 5% of patients on triple therapy experienced renal insufficiency stage 3 (eGFR<60 mL/min).
However, some authors have questioned whether the decrease in eGFR noted is clinically significant, as TVR was shown to inhibit drug New generation protease inhibitors like SMV, paritaprevir and grazoprevir are all entirely hepatically metabolized and thus expected to have excellent renal safety profiles. [29] [30] [31] We did not find an increased frequency of AKI in patients using SOF/SMV when compared to patients taking SOF without SMV (data not shown).
A recent publication showed that patients treated with a paritaprevir-containing regimen presented a higher incidence of AKI when compared to a SOF-based regimen, however, more patients with baseline chronic kidney disease were included in the former group, (Butt) thus obscuring interpretation of results. 15 Unfortunately, we did not analyze patients treated with paritaprevir and therefore were not able to further investigate toxicity from new generation protease inhibitors. Renal elimination of SMV and grazoprevir is negligible at <1%, and similarly, the regimen containing paritaprevir/ritonavir, ombitasvir and dasabuvir is minimally renally excreted (<11.3%).
32-34
Based on their limited renal excretion, grazoprevir and elbasvir as well as the combination of paritaprevir/ritonavir, ombitasvir and dasabuvir have been evaluated in patients with advanced chronic kidney disease or on hemodialysis showing that these agents are extremely safe and highly effective. 35, 36 The finding that ascites was associated with the occurrence of AKI during antiviral therapy stresses the importance of close monitoring of patients with decompensated cirrhosis. Renal function gradually deteriorates due to hemodynamic changes associated with decompensated liver disease. 37 Whether our observation of impaired renal function in these patients is induced by antiviral therapy or whether it is related to progression of liver disease and/or its treatment, is not clear.
Patients taking diuretics were at higher risk of AKI during treatment as were patients taking NSAIDs, a class of drugs that are contraindicated in patients with cirrhosis due to their impairment of renal blood flow, particularly in the setting of portal hypertension. 38 There are some limitations of our study. Due to its retrospective character, the choice of anti-viral regimens was made by the treating physician, however, patients were treated in academic centres and all consecutive patients were included, limiting selection bias.
Although missing data always present challenges, we had very low rates of missing data and do not believe that they significantly affected the results of our study. Given the reduced number of AKI events noted in the subgroup of patients with SOF-based regimens,
we had limited ability to do a comprehensive multivariable analysis to identify more factors associated with AKI (ie, hypertension).
Finally, the HCV TARGET registry and others have suggested that patients with baseline impairment of renal function are at higher risk of AKI during SOF-based therapy, however, we had few patients with eGFR below 60 mL/min at baseline and a subanalysis of this population could thus not be performed. Nevertheless, approximately 19% of these patients experienced AKI.
Despite inclusion of patients with more advanced liver disease, the risk for AKI was lower for patients treated with SOF-based regimens compared to TVR/BOC-based regimens. Although AKI was seen in 11% of the patients treated with SOF-based therapy, it was reversible in almost all cases. Patients with ascites and patients using
NSAIDs have an increased risk for AKI during SOF-based antiviral therapy. Monitoring of renal function and standard nephroprotective measures are suggested when using SOF-based regimens, particularly in patients with advanced cirrhosis and portal hypertension, or in those with comorbidities potentially affecting the kidneys.
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